Market capitalization | $38.71m |
Enterprise Value | $-18.76m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.24 |
EV/Sales (TTM) EV/Sales | -6.90 |
P/S ratio (TTM) P/S ratio | 14.23 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue growth (TTM) Revenue growth | 27.61% |
Revenue (TTM) Revenue | $2.72m |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
3 Analysts have issued a Singular Genomics Systems Inc forecast:
3 Analysts have issued a Singular Genomics Systems Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 2.72 2.72 |
28%
28%
|
|
Gross Profit | -8.15 -8.15 |
14%
14%
|
|
EBITDA | -92 -92 |
1%
1%
|
EBIT (Operating Income) EBIT | -99 -99 |
1%
1%
|
Net Profit | -92 -92 |
2%
2%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Singular Genomics Systems, Inc. engages in the development and commercialization of proprietary sequencing solutions. It develops two integrated solutions: G4 Instrument and PX Instrument. The G4 Instrument operates as a benchtop next generation sequencer designed to produce fast and accurate genetic sequencing results. The PX Instrument combines single cell and spatial analysis, genomics, and proteomics in one integrated instrument providing a versatile multiomics solution. The company was founded by Eli Glezer and Andrew Spaventa in June 2016 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | Andrew Spaventa |
Employees | 265 |
Founded | 2016 |
Website | www.singulargenomics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.